NEWS
Verastem Oncology Receives FDA Orphan Drug Designation for Avutometinib and Defactinib for the Treatment of Pancreatic Cancer
Verastem Oncology (Nasdaq: VSTM) has received FDA Orphan Drug Designation for avutometinib and defactinib in treating pancreatic cancer. This combination therapy, along with standard chemotherapy, showed promising results in the ongoing RAMP 205 trial for first-line metastatic pancreatic cancer. Initial interim data presented at ASCO 2024 revealed an 83% confirmed partial response rate in the dose level 1 cohort. The company plans to report updated data from the trial in Q1 2025. The Orphan Drug Designation recognizes the unmet need in pancreatic cancer treatment and offers benefits such as tax credits and potential market exclusivity.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1170Followers
73Following
8184Visitors
Follow
Salmon Klein : great news!! isn't?!
151323992 : Like with that news it should be on a rampage....
151323992 : This won't go up until a clinical trial takes place I assume
Jaguar8 OP 151323992 : It already has clinical trial data to support an ODD.
Salmon Klein Jaguar8 OP : why the negative reaction today? I was in a few days ago at 3... should have sold yesterday?....I personally like this stock, financials are healthy, clinical results seems going well...what's your view here?